$119,160,691
to SHIONOGI INC
LATE-STAGE DEVELOPMENT, FDA MARKETING AUTHORIZATION, PROCUREMENT, AND STOCKPILE OF ANTIBIOTICS FOR THE TREATMENT OF DRUG-RESISTANT SECONDARY BACTERIAL INFECTIONS AND/OR THE TREATMENT OR PEP OF INFECTIONS CAUSED BY BIOTHREAT PATHOGENS.
Verbatim from USAspending.gov. Capitalization, abbreviations, and codes are unchanged.
What the model surfaced from this award
Late-stage development, FDA approval, procurement, and stockpiling of antibiotics for drug-resistant bacterial infections and biothreat pathogens.
Addresses critical gap in medical countermeasures for antimicrobial resistance and biological threats; 10-year commitment signals sustained biodefense investment.
Secures domestic pharmaceutical manufacturing capacity for strategic antibiotics; reduces reliance on foreign suppliers for critical medical countermeasures.
Reduces U.S. dependence on Chinese active pharmaceutical ingredients for antibiotics; strengthens domestic biodefense resilience against state-sponsored biological threats.
Generated by award_classification v2.1.0 via claude-haiku-4-5-20251001 on 2026-05-26. Cost: $0.002963.
- USAspending.gov — all awards for this UEI →
- SAM.gov entity registration →
- Award record ingested from usaspending. Source identifier CONT_AWD_75A50126C00004_7505_-NONE-_-NONE-.
The Buildout does not edit federal records. Any inaccuracy reflects the upstream source; it will update here when corrected there.